Biopharma Services Usa
Div Biopharma Services Usa Inc.
CAGE Code: 7G0A9
NCAGE Code: 7G0A9
Status: Active
Type: Commercial Supplier
Summary
Biopharma Services Usa, Div Biopharma Services Usa Inc. is an Active Commercial Supplier with the Cage Code 7G0A9.
Address
10330 Old Olive Street Rd
Creve Coeur MO 63141-5933
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Inspicio Partners Llc Peoria And Pekin Union Railway Barrington Broadcasting Peoria Impressions Poly-Generics Co Energy Direction Laser Vision Centers Inc. M And W Contractors Inc Village Of Creve Cour Kellers Peoria Harbor Service Children's Center Of Tazewell County Citishred Llc Creve Coeur Village Of First Bank Bentley Michael J Dds Ltd Creve Coeur School District 76 Village Of Creve Coeur Apex Roofing Inc Bisco Industries Inc. Rjd Revocable Living Trust
Frequently Asked Questions (FAQ) for CAGE 7G0A9
- What is CAGE Code 7G0A9?
- 7G0A9 is the unique identifier used by NATO Organizations to reference the physical entity known as Biopharma Services Usa Div Biopharma Services Usa Inc. located at 10330 Old Olive Street Rd, Creve Coeur MO 63141-5933, United States.
- Who is CAGE Code 7G0A9?
- 7G0A9 refers to Biopharma Services Usa Div Biopharma Services Usa Inc. located at 10330 Old Olive Street Rd, Creve Coeur MO 63141-5933, United States.
- Where is CAGE Code 7G0A9 Located?
- CAGE Code 7G0A9 is located in Creve Coeur, MO, USA.
Contracting History for CAGE 7G0A9 Most Recent 25 Records
- 75F40120F19005
- Modification To Add Additional Funding To Cover Unforeseen Cost Increases In Subject Recruitment Due To The Covid-19 Pandemic.
- 1 Jun 2022
- Modification To Add Additional Funding To Cover Unforeseen Cost Increases In Subject Recruitment Due To The Covid-19 Pandemic.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,845,196.00
- Department Of Health And Human Services (Hhs)
- 75F40120F19005
- Modification To Extend The Period Of Performance End Date To 05/31/2022. A Revised Deliverable Table Is Attached
- 4 Jan 2022
- Modification To Extend The Period Of Performance End Date To 05/31/2022. A Revised Deliverable Table Is Attached
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,825,452.00
- Department Of Health And Human Services (Hhs)
- 75F40120F19005
- Modification To Revised The Human Subject Language In The Sow And Extend The Period Of Performance End Date To 01/03/2022.
- 28 Jun 2021
- Modification To Revised The Human Subject Language In The Sow And Extend The Period Of Performance End Date To 01/03/2022.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,825,452.00
- Department Of Health And Human Services (Hhs)
- 75F40119F19004
- Modification To Revise The Sow, Deliverable Table, Change The Cor And Extend The Pop
- 23 May 2022
- Modification To Revise The Sow, Deliverable Table, Change The Cor And Extend The Pop
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,261,300.00
- Department Of Health And Human Services (Hhs)
- 75F40119F19004
- Sow Changes - "Pharmacokinetic (Pk) Study Of Opioid Drug Products Following Oral Ingestion Of Chewed Products
- 24 Mar 2023
- Sow Changes - "Pharmacokinetic (Pk) Study Of Opioid Drug Products Following Oral Ingestion Of Chewed Products
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,470,791.00
- Department Of Health And Human Services (Hhs)
- 75F40118F01002
- The Purpose Of This Modification Is To Obligate Additional Funding And Extend The Period Of Performance.
- 27 Apr 2023
- The Purpose Of This Modification Is To Obligate Additional Funding And Extend The Period Of Performance.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,877,830.00
- Department Of Health And Human Services (Hhs)
- 75F40118F01002
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists
- 23 Jan 2023
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,808,265.00
- Department Of Health And Human Services (Hhs)
- 75F40118F01002
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0008 - Adjust The Deliverables Schedule, Add Funding, Change Cor's And Extend The Period Of Performance.
- 17 Nov 2022
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0008 - Adjust The Deliverables Schedule, Add Funding, Change Cor's And Extend The Period Of Performance.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,808,265.00
- Department Of Health And Human Services (Hhs)
- 75F40118F01002
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0005 - Adjust The Deliverables Schedule, Add Funding, And Extend The Period Of Performance.
- 23 Nov 2021
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0005 - Adjust The Deliverables Schedule, Add Funding, And Extend The Period Of Performance.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,788,705.00
- Department Of Health And Human Services (Hhs)
- 75F40118F01002
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0005 - Adjust The Deliverables Schedule, Add Funding, And Extend The Period Of Performance.
- 24 Sep 2021
- Nasal Pharmacokinetic (Pk)Pharmacodynamic (Pd) Studies Of Oral Combination Products Containing Opioid Agonists And Antagonists Mod 0005 - Adjust The Deliverables Schedule, Add Funding, And Extend The Period Of Performance.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,788,705.00
- Department Of Health And Human Services (Hhs)